|
Oxford BioMedica PLC on Wednesday said it signed a license and supply agreement with an unnamed new partner.
Shares were up 4.3% at 439.50 pence each on Wednesday morning in London.
The Oxford, England-based gene and cell therapy company said the deal is with an undisclosed US-based late-stage cell and gene therapy company, putting into place a five-year clinical supply arrangement.
Oxford BioMedica will grant the partner a non-exclusive license to utilise its LentiVector platform under the pact for its application in their lead programme, a cell-based therapy targeting a rare indication.
In return, it will receive undisclosed upfront payments and additional payments ‘related to development and manufacturing of lentiviral vectors for use in clinical trials’. Lentiviral particles are used for cell engineering.
Chair and Interim Chief Executive Officer Roch Doliveux said: ‘This partnership further demonstrates Oxford Biomedica's world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year. We look forward to continuing to build upon our position as a partner of choice to deliver life-saving cell and gene therapies to patients.’
In July, the company signed a license agreement with an unnamed US-based biotechnology company to advance new cell therapies.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
